Medicinal Chemistry for Neurotherapeutics Program (MCNP)

The National Institute of Neurological Disorders and Stroke (NINDS), National Institutes of Health (NIH), DHHS, through the NIH Blueprint Program Initiative and more specifically through the Medicinal Chemistry for Neurotherapeutics Program (MCNP) has awarded a 5-year contract to Albany Molecular Research, Inc., Albany, New York for the period August 17, 2011 through August 16, 2016. This contract shall provide medicinal chemistry services as part of an overall program effort to develop preclinical drug candidates - optimal drug leads that are ready for Investigational New Drug (IND) - enabling pharmacology and toxicology studies. The base contract award amount of $9,951,608 will cover acquisition of medicinal chemistry services associated with an initial project cohort called "Blueprint Cohort #1." In addition to the base contract, the Government shall also have the right to exercise a variety of additional individual medicinal chemistry study options during the five-year period of this contract. Future possible contract options are as follows: -- One (1) additional Blueprint Cohort, i.e. Blueprint Cohort #2, at a total estimated value of $9,644,514; -- Up to thirty (30) individual exploratory chemistry studies during the contract period, at a total estimated value of $4,543,772 if all 30 options exercised; -- Up to nine (9) Hit-to-Lead chemistry studies during the contract period, at a total estimated value of $10,595,341 if all nine options exercised; and -- Up to six (6) Lead-Optimization studies during the contract period, at a total estimated value of $8,222,223 if all six options exercised. Since the base contract and any subsequent option represents separate and distinct nonseverable requirements, each will be fully funded at the time each is awarded. Base contract and all possible options awarded on a cost reimbursement basis due to the nature and uncertainty of testing reiterations that might be necessary for an individual compound.